Sign In
Last checked at 
1 Dec 2009 10:05
ο»Ώ
Hikma Pharmaceuticals PLC - Voting Rights and Capital
LONDON,Β 1Β DecemberΒ 2009:Β Hikma Pharmaceuticals PLC (LSE: HIK) (NasdaqDubai: HIK)Β notifies the marketΒ thatΒ asΒ atΒ 30 NovemberΒ 2009Β itsΒ capital consistsΒ ofΒ 191,564,907Β ordinary sharesΒ with voting rights.Β There are no shares held in treasury.
The above figure (191,564,907) may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, Hikma Pharmaceuticals PLC under the FSA's Disclosure and Transparency Rules.Β
- ENDS -
Enquiries:
|
Hikma Pharmaceuticals PLC |
|
|
Henry Knowles Company Secretary |
+44 20 7399 2760 |
About Hikma
Hikma Pharmaceuticals PLC is a fast growing multinational group focused on developing, manufacturing and marketing a broad range of both branded and non-branded generic and in-licensed pharmaceutical products. Hikma's operations are conducted through three businesses: "Branded", "Injectables" and "Generics". Hikma's operations are based principally in the Middle East and North Africa ("MENA") region, where it is a market leader and sells across 17 countries, theΒ United StatesΒ andΒ Europe. In 2008, theΒ Group achieved revenues of $580.7 million (2007 $449Β million) and profit attributable to shareholders was $57.1 million (2007 $63Β million). For news and other information, please visitΒ www.hikma.com.
Follow the stocks
